170 results on '"Zile, Michael R"'
Search Results
2. Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to
3. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
4. Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
5. Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials
6. Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
7. A Novel Heart Failure Diagnostic Risk Score Using a Minimally Invasive Subcutaneous Insertable Cardiac Monitor
8. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
9. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction
10. Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction
11. Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial
12. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan
13. Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides
14. Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure
15. Baroreflex Activation Therapy in Patients with Heart Failure with a Reduced Ejection Fraction
16. Hemodynamically-Guided Management of Heart Failure Across the Ejection Fraction Spectrum: The GUIDE-HF Trial
17. Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection Fraction
18. Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF
19. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
20. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
21. Loop Diuretic Prescription and Long-Term Outcomes in Heart Failure: Association Modification by Congestion
22. Incidence and Outcomes of Pneumonia in Patients With Heart Failure
23. Systolic Blood Pressure and Outcomes in Older Patients with HFpEF and Hypertension
24. Racial difference in atrial size and extracellular matrix homeostatic response to hypertension: Is this a potential mechanism of reduced atrial fibrillation in African Americans?
25. Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation
26. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction
27. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials
28. Changes in Myocardial Microstructure and Mechanics With Progressive Left Ventricular Pressure Overload
29. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
30. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper
31. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
32. Seipin Knockout Mice Develop Heart Failure With Preserved Ejection Fraction
33. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial
34. Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure
35. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction
36. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF
37. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
38. Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis
39. B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial
40. Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF
41. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women
42. Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate
43. Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Trial-Level Analysis
44. Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee
45. Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease
46. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
47. Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure
48. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure
49. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial
50. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.